Linzess

How Does Linzess Work?

Linzess (linaclotide) is a guanylate cyclase-C (GC-C) agonist. After you swallow the capsule, linaclotide passes into the small intestine and binds to GC-C receptors on the surface of intestinal epithelial cells. This activates the enzyme guanylate cyclase, triggering the production of cyclic guanosine monophosphate (cGMP) inside the cells.

The elevated cGMP then activates chloride and bicarbonate channels, causing these ions to flow into the intestinal lumen. Water passively follows the ions, increasing fluid content in the intestine. The result is softer, easier-to-pass stools and faster GI transit. Linzess also reduces visceral pain signaling in IBS-C by allowing some extracellular cGMP to diffuse to pain-sensing nerves below the epithelium, reducing their sensitivity.

Importantly, Linzess is negligibly absorbed into the bloodstream. It works exclusively in the gut, which is why it has virtually no drug-drug interactions and does not cause systemic side effects. All side effects are GI-related, with diarrhea being the most common.

How Hard Is It to Find Linzess in Stock?

Linzess is not on any FDA or ASHP drug shortage list as of 2026. The drug is manufactured by AbbVie and has been continuously available since its 2012 approval. However, patients frequently report difficulty filling their prescription due to a combination of factors: high brand-name cost ($680–$736 per month), insurance prior authorization requirements, step therapy, and inconsistent stocking at smaller pharmacies.

Large chain pharmacies (CVS, Walgreens, Walmart, Costco) and mail-order pharmacies typically stock Linzess more reliably than independent pharmacies. Patients who have difficulty locating Linzess in stock are encouraged to use

medfinder, which calls pharmacies near you to check which ones have your medication in stock and can fill your prescription—with results texted directly to you.

Who Can Prescribe Linzess?

Linzess (linaclotide) is not a controlled substance and has no DEA scheduling restrictions. This means any licensed healthcare provider with prescribing authority can write a Linzess prescription without special registration. There are no federal restrictions on prescribing it via telehealth.

Types of providers who commonly prescribe Linzess:

• Gastroenterologists (most common prescribers)
• Primary care physicians (family medicine, internal medicine)
• Nurse practitioners (NPs) and physician assistants (PAs)
• Pediatricians and pediatric gastroenterologists (for children 2+ with FC or children 7+ with IBS-C)

Linzess is available via telehealth platforms for appropriate candidates. Because it is not a controlled substance, telehealth providers can prescribe it after a clinical evaluation without any additional state or federal restrictions. Established patients needing prescription renewals can particularly benefit from telehealth convenience.

Is Linzess a Controlled Substance?

No. Linzess (linaclotide) is not a controlled substance and is not scheduled by the DEA. It can be prescribed by any licensed healthcare provider with prescribing authority, including primary care physicians, gastroenterologists, internists, nurse practitioners, and physician assistants. There are no special DEA registration requirements to prescribe it, and it can be prescribed via telehealth in most states without any additional restrictions.

Prescriptions for Linzess may be called in, faxed, or sent electronically to pharmacies. Because it is not a controlled substance, there are no limits on the number of refills that can be written on a single prescription, and prescriptions can be transferred between pharmacies without restriction.

Common Side Effects of Linzess

The most common side effects of Linzess (linaclotide) are all gastrointestinal in nature, reflecting its local mechanism of action in the gut:

• Diarrhea: The most common side effect, reported in up to 20% of patients; dose-related; onset often within the first 2 weeks of treatment
• Abdominal pain: Lower and upper abdominal cramping
• Flatulence (gas)
• Abdominal distension (bloating)
• Headache: Often related to fluid loss from diarrhea

Serious side effects — stop taking Linzess and seek medical care if you experience:

• Severe diarrhea with dizziness, fainting (syncope), low blood pressure, or electrolyte abnormalities (hypokalemia, hyponatremia) requiring hospitalization
• Signs of serious allergic reaction: hives, difficulty breathing, swelling of face, lips, tongue, or throat (anaphylaxis or angioedema)
• Black, bloody, or tarry stools (possible GI bleeding)

CRITICAL WARNING: Linzess is contraindicated in children under 2 years of age. It can cause severe diarrhea and fatal dehydration in young children. Keep Linzess out of reach of children.

Final Thoughts on Linzess

Linzess (linaclotide) is a well-established, effective prescription treatment for IBS with constipation, chronic idiopathic constipation, and functional constipation in children. Approved since 2012 and used by hundreds of thousands of patients, it remains a first-line recommendation in major gastroenterology guidelines. Its local-acting mechanism makes it uniquely well-suited for IBS-C, where both constipation and abdominal pain need treatment.

The main challenges with Linzess in 2026 are cost and access. As a brand-name-only drug, its retail price of $680–$736 per month is prohibitive without insurance or savings programs. The good news: the Linzess Savings Program can reduce costs to $30/month for commercially insured patients, and the AbbVie Patient Assistance Foundation provides free medication for qualifying uninsured patients.

If you're struggling to find Linzess at a pharmacy near you, medfinder calls pharmacies in your area to identify which ones have it in stock and can fill your prescription—then texts you the results, saving you hours of frustrating phone calls.